Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.
Several human mucosal fluids are known to possess an innate ability to inhibit human immunodeficiency virus type 1 (HIV-1) infection and replication in vitro. This study compared the HIV-1 inhibitory activities of several mucosal fluids, whole, submandibular/sublingual (sm/sl), and parotid saliva, breast milk, colostrum, seminal plasma, and cervicovaginal secretions, from HIV-1-seronegative donors by using a 3-day microtiter infection assay. A wide range of HIV-1 inhibitory activity was exhibited in all mucosal fluids tested, with some donors exhibiting high levels of activity while others showed significantly lower levels. Colostrum, whole milk, and whole saliva possessed the highest levels of anti-HIV-1 activity, seminal fluid, cervicovaginal secretions, and sm/sl exhibited moderate levels, and parotid saliva consistently demonstrated the lowest levels of HIV-1 inhibition. Fast protein liquid chromatography gel filtration studies revealed the presence of at least three distinct peaks of inhibitory activity against HIV-1 in saliva and breast milk. Incubation of unfractionated and fractionated whole saliva with antibodies raised against human lactoferrin (hLf), secretory leukocyte protease inhibitor (SLPI), and, to a lesser extent, MG2 (high-molecular-weight mucinous glycoprotein) reduced the HIV-1 inhibitory activity significantly. The results suggest that hLf and SLPI are two key components responsible for HIV-1 inhibitory activity in different mucosal secretions. The variation in HIV inhibitory activity between the fluids and between individuals suggests that there may be major differences in susceptibility to HIV infection depending both on the individual and on the mucosal fluid involved.
Kazmi
Shamim H
SH
Oral AIDS Research Unit, Department of Oral Medicine and Immunology, King's College London Dental Institute at Guy's, King's College, and St. Thomas' Hospitals, Floor 28, Guy's Tower, King's College London, London SE1 9RT, United Kingdom.
Naglik
Julian R
JR
Sweet
Simon P
SP
Evans
Robert W
RW
O'Shea
Siobhan
S
Banatvala
Jangu E
JE
Challacombe
Stephen J
SJ
D019380:Anti-HIV Agents / Q000032:analysis*; D019138:Antibodies, Blocking / Q000032:analysis / Q000502:physiology; D003602:Cytotoxicity, Immunologic; D015658:HIV Infections / Q000276:immunology* / Q000378:metabolism / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal; D007781:Lactoferrin / Q000032:analysis / Q000502:physiology; D012463:Saliva / Q000737:chemistry / Q000276:immunology* / Q000821:virology*; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000032:analysis / Q000502:physiology
D019380:Anti-HIV Agents; D019138:Antibodies, Blocking; D053481:Secretory Leukocyte Peptidase Inhibitor; D007781:Lactoferrin